Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a registrational Phase II breast cancer trial.

Oncolytics Biotech has dosed the first patient with a combination therapy of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) for metastatic pancreatic cancer as part of the Gastrointestinal tumOrs trials.

Oncolytics Biotech released promising results Thursday from its Phase I/II GOBLET study in advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) that support plans to advance the program into Phase III. 

Californian immuno-oncology biotech CG Oncology has reeled in a $47 million series D—and, surely, an IPO isn’t far behind—as it looks to phase 3 trials.

The funding was led by new investor Kissei Pharmaceutical with help from existing investors ORI Healthcare Fund, Camford Capital and Perseverance Capital Management.

ncolytics Biotech (NASDAQ:ONCY) posted its earnings results on Friday. The company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.25), MarketWatch Earnings reports.